Streetbeat News

Products Services

BBIO

BridgeBio Pharma's drug acoramidis shows a 42% reduction in mortality and heart hospitalizations in a Phase 3 study for ATTR-CM. The company has submitted a New Drug Application to the FDA, with a decision expected by November 2024.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 7:23 am

MDT

Medtronic's PulseSelect PFA System shows a 98% success rate in treating atrial fibrillation, with high lesion durability. The study results were presented at the APHRS meeting, highlighting the system's effectiveness and global expansion.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 7:20 am

ETHUSD

Ethereum staking yields are set to surpass US federal funds rates, driven by potential Fed rate cuts and rising transaction fees. This could support Ethereum's price, though not as the primary catalyst. Interest in Ether staking has increased since the Shapella Upgrade, but traditional investors lack access to staking through ETFs.

Portfolio Pulse from Aniket Verma

September 30, 2024 | 7:17 am

ALNY

Alnylam Pharmaceuticals presented new data from the HELIOS-B Phase 3 study of vutrisiran, showing its potential as a first-line therapy for ATTR amyloidosis with cardiomyopathy. The data demonstrated significant improvements in cardiac biomarkers and echocardiographic parameters, indicating a disease-modifying effect. Alnylam plans to complete global regulatory submissions by the end of the year.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 7:05 am

MESO

Mesoblast Limited has secured a $50 million convertible note deal with its largest shareholder, contingent on FDA approval of its product Ryoncil for treating SR-aGvHD in children. The funding will support the company's commercial launch strategy.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 6:54 am

VRNA

Verona Pharma will present results from its Phase 3 ENHANCE studies on Ohtuvayre, a novel COPD treatment, at the CHEST 2024 meeting. The studies show Ohtuvayre's efficacy in improving lung function and reducing exacerbations in COPD patients.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 6:44 am

CME

CME Group is set to launch Spodumene CIF China Futures on October 28, 2024, expanding its battery metals suite. This move aims to enhance hedging capabilities in the lithium value chain, with support from industry players like Albemarle and Liontown.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 6:42 am

NVDA

Former BCG executive Phil Panaro predicts Nvidia's stock could reach $800 by 2030, driven by AI and Web3 advancements. Nvidia's revenue is expected to grow significantly, with a major boost from its upcoming AI chip, Blackwell. Despite some skepticism, Nvidia's innovative approach and market potential remain strong.

Portfolio Pulse from Kaustubh Bagalkote

September 30, 2024 | 6:35 am

BYDDF

BYDDY

BYD is recalling nearly 97,000 EVs due to overheating risks in the CEPS system, potentially causing fires. The recall affects Dolphin and Yuan PLUS models produced between November 2022 and December 2023. BYD will fix the issue at no cost to customers.

Portfolio Pulse from Anan Ashraf

September 30, 2024 | 6:17 am

COST

TSM

Economist Ben Golub warns of a potential US shipping strike affecting 36 ports, reminiscent of the 2021-2022 supply chain crisis. The strike could impact industries reliant on complex supply networks, including the semiconductor sector. Companies like Costco are taking measures to mitigate potential disruptions.

Portfolio Pulse from Kaustubh Bagalkote

September 30, 2024 | 3:53 am